Phreesia, Inc.

Phreesia, Inc. (PHR) Market Cap

Phreesia, Inc. has a market capitalization of $663.2M.

Price: $10.73

0.12 (1.13%)

Market Cap: 663.24M

NYSE · time unavailable

CEO: Chaim Indig

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-07-18

Website: https://www.phreesia.com

Phreesia, Inc. (PHR) - Company Information

Market Cap: 663.24M|Sector: Healthcare

Company Profile

Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.

Analyst Sentiment

82%
Strong Buy

From 19 Active Polls

1Y Forecast: $13.57

▲ +26.5% Potential Upside

Consensus Target Metrics

Low Bound

$9

Median

$12

High Bound

$22

Average

$14

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$13.57
▲ +26.47% Upside
Low Target
$9.00
-16% Risk
Median Target
$12.00
12% Mid
High Target
$22.00
105% Max
Consensus
Buy
18 / 25 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MApr 30, 2026Jan 31, 2026Oct 31, 2025Jul 31, 2025Apr 30, 2025Jan 31, 2025Oct 31, 2024Jul 31, 2024
Market Cap ($M)6635618021,3471,5981,4711,6591,0591,435
Enterprise Value ($M)6815798311,2511,5121,3961,5929981,369
Price to Earnings Ratio (P/E)70.5047.38156.8979.49612.73-93.98-64.687.03-20.12
Price/Earnings-to-Growth Ratio (PEG)15.5628.0430.28538.57-16.48-23.981.53-22.68
Price to Sales Ratio (P/S)1.344.296.3111.2013.6312.6915.129.9114.05
Price to Book Ratio (P/B)1.821.562.384.215.365.216.264.165.71
Price to Free Cash Flow Ratio (P/FCF)9.1234.2825.79110.48122.26197.19180.32660.54392.21
Enterprise Value to Sales (EV/Sales)4.426.5410.4012.9012.0414.529.3513.41
Enterprise Value to EBITDA (EV/EBITDA)16.0533.88160.6596.84208.96337.61743.31-159.09-149.52
Debt to Equity Ratio0.420.260.300.030.040.060.070.080.07

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PHREESIA INC (PHR) — Investment Overview

🧩 Business Model Overview

Phreesia provides “digital front door” software used by healthcare providers to automate patient intake and pre-visit workflows. The value chain typically runs as: (1) configure patient-facing digital forms and intake workflows, (2) integrate intake data with provider systems used for clinical and administrative operations, and (3) route completed information into downstream processes that affect scheduling, registration, and billing readiness.

Deployment is oriented around embedding into established patient check-in and visit preparation workflows, creating operational stickiness once intake processes and system connections are in place.

💰 Revenue Streams & Monetisation Model

The monetisation model is primarily subscription-based, often structured around per-provider or per-location access and usage tiers, with revenue tied to active deployments rather than one-time software licenses. A portion of economics can also depend on add-on services or implementation/support activities associated with onboarding and workflow configuration.

Margin drivers are concentrated in software gross margin (low incremental cost per incremental patient interaction), scale benefits from centralized product development, and operating leverage from the sales/implementation motion once a provider network is established. Retention and expansion are key because switching away from integrated intake workflows is operationally disruptive.

🧠 Competitive Advantages & Market Positioning

Core moat: High Switching Costs (workflow and integration “data gravity”). Phreesia’s product is embedded in patient intake operations and connected to provider systems. That integration work—and the resulting downstream process changes (registration accuracy, reduced manual rework, and improved administrative throughput)—creates practical switching costs for providers. Competitors can offer overlapping front-end experiences, but displacing an operationally integrated intake workflow typically requires re-implementation, validation, and re-training across teams.

Competitive benchmarking (examples):

  • RevSpring: focuses on patient financial engagement and digital tools tied to payment readiness; overlaps in patient-facing automation but competes more on financial workflows than on end-to-end intake data capture.
  • ModMed: targets digital patient intake and engagement within provider operations; overlaps directly in intake automation where both platforms can be evaluated as “digital front door” solutions.
  • athenahealth / EHR-centric ecosystems: offer intake and workflow capabilities bundled or complemented by platform services; the advantage typically rests on broader system breadth, while Phreesia differentiates through specialized intake automation and deployment into existing workflows.

Positioning versus rivals: Phreesia’s industry focus is intake workflow automation at the patient’s point of interaction with the provider. EHR-centric competitors can bundle similar capabilities, but they face trade-offs in deploying specialized workflows across diverse operational environments. Financial engagement players may provide adjacent functionality but may not fully substitute for intake automation embedded in front-end visit preparation.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by structural demand for administrative automation and improved patient experience without proportional increases in labor. Key drivers include:

  • Expansion of outpatient and multi-site delivery models: more locations and front-desk volume increases the economic case for standardized intake workflows.
  • Digitization of front-office processes: providers face pressure to reduce manual registration work, improve data completeness, and streamline visit readiness.
  • Data integration and workflow standardization: as providers modernize systems and seek interoperability, specialized intake tools can scale through repeatable implementations.
  • Operational efficiency incentives: administrative cost control and capacity management elevate ROI for automation solutions that improve throughput and reduce errors requiring manual correction.
  • Broader “digital patient journey” adoption: intake automation acts as a platform entry point that can support incremental workflow enhancements within the visit lifecycle.

TAM expansion is driven less by a one-time technology refresh and more by ongoing provider network modernization—where embedded workflow solutions can sell and expand across geographies, specialties, and facility types.

⚠ Risk Factors to Monitor

  • Integration and interoperability risk: product value depends on reliable connectivity to provider systems and workflows. Integration complexity or failures can increase churn risk or slow sales cycles.
  • Cybersecurity and privacy exposure: patient intake data is sensitive; breaches or compliance lapses can damage trust and lead to contract termination or regulatory scrutiny.
  • Buyer budget and utilization risk: provider demand can fluctuate with payer mix, reimbursement pressure, and administrative budget constraints, impacting procurement timing and renewal economics.
  • Competitive substitution: large platform providers may expand native intake features, and point-solution vendors may compete on price or packaging, compressing margins unless differentiation remains strong.
  • Implementation execution: onboarding quality affects retention. Poor configuration, workflow mismatch, or training gaps can reduce operational benefits and lead to underutilization.

📊 Valuation & Market View

Healthcare software companies with subscription revenue are typically valued on a combination of EV/Revenue (or EV/ARR), growth rate, and profitability trajectory rather than near-term earnings. Market focus tends to center on:

  • Recurring revenue quality: retention and expansion dynamics (net revenue retention), indicating the strength of switching costs and embedded workflows.
  • Unit economics: gross margin stability and operating leverage as sales and onboarding scale.
  • Sales efficiency: customer acquisition costs relative to lifetime value, influenced by deployment success and time-to-value.
  • Durability of demand: sustained provider digitization and administrative automation spending.

In this sector, valuation multiples expand when growth accelerates and retention remains resilient, and contract when implementation risk rises or churn increases—particularly if providers treat these tools as replaceable commodity software.

🔍 Investment Takeaway

Phreesia’s long-term thesis rests on operating workflow adoption—where integrated patient intake processes create practical switching costs. With healthcare providers continuing to digitize front-office operations and reduce administrative friction, Phreesia is positioned to benefit from recurring deployments and expansion within multi-location delivery networks, provided integration quality, security, and customer outcomes remain consistent.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for PHR.

globenewswire.com2026-07-29

PHREESIA, INC. (NYSE: PHR) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

defenseworld.net2026-07-28

Phreesia (NYSE:PHR) & EUDA Health (NASDAQ:EUDA) Head-To-Head Review

EUDA Health (NASDAQ: EUDA - Get Free Report) and Phreesia (NYSE: PHR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Profitability This table compares EUDA Health and Phreesia's

businesswire.com2026-07-23

Phreesia and March of Dimes Partner to Help Strengthen Physician-Patient Conversations and Improve the Health of Moms and Babies

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia and March of Dimes announce a partnership to enhance critical physician-patient conversations during prenatal and postpartum appointments.

gurufocus.com2026-07-22

A Look at Phreesia Inc (PHR) After 5.6% Decline -- GF Value $27.06 vs Price $10.01

On July 22, 2026, Phreesia Inc (PHR) shares fell 5.6% to a current price of $10.01. This decline comes amidst a 52-week range that has seen highs of $32.76 and

zacks.com2026-07-21

Should Value Investors Buy Phreesia (PHR) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

businesswire.com2026-07-21

MediFind Launches AI-Powered Chatbot to Help Patients Find and Book the Right Provider

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--MediFind, a data-powered online provider directory offered by Phreesia, is announcing the launch of Chloe, its new “Find the Right Provider” chatbot.

prnewswire.com2026-07-16

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines - PHR

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Phreesia, Inc. ("Phreesia" or the "Company") (NYSE: PHR).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

globenewswire.com2026-07-16

PHREESIA, INC. (PHR) INVESTIGATION ALERT: Bernstein Liebhard Announces Investigation of Phreesia, Inc.

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you currently own shares of Phreesia, Inc. (NYSE: PHR)? Did you purchase any of your shares prior to May 8, 2025?

globenewswire.com2026-07-14

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines – PHR

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

globenewswire.com2026-07-13

DEADLINE ALERT for PHR, SRAD, CVLT, VERI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

newsfilecorp.com2026-07-13

PHR FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Phreesia, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 13 Deadline in Securities Class Action - PHR

New York, New York--(Newsfile Corp. - July 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the "Class Period"), of the important July 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased Phreesia common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

globenewswire.com2026-07-13

PHR DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 13 Deadline in Securities Class Action - PHR

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

newsfilecorp.com2026-07-13

Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - July 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Phreesia securities between May 8, 2025 and March 30, 2026, both dates inclusive (the "Class Period").

gurufocus.com2026-07-13

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Phreesia, Inc. (“Phreesia” or the “Co

businesswire.com2026-07-13

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

NEW YORK--(BUSINESS WIRE)---- $PHR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR) and reminds investors of the July 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recov.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-30

"PHR reported Q1’27 (ended 2026-04-30) revenue of $130.9M and net income of $6.5M (EPS $0.05), versus a much weaker prior quarter (Q4’26) with net income of $1.3M. QoQ revenue rose 3.1% (from $127.1M), and net income surged 401% (from $1.3M). On a YoY basis, revenue grew 12.8% (from $115.9M) and net income improved versus the prior-year loss of $(3.9)M to a profit of $6.5M—turning the bottom line materially. Profitability improved meaningfully: net margin expanded to 4.95% from 1.02% QoQ and from -3.38% YoY. The gross margin also strengthened (Q1’27 gross margin 86.5% vs 43.0% in Q4’26), while operating income and operating margin moved back to positive (operating margin 5.15% vs 2.89% QoQ and -2.84% YoY). Cash flow quality improved despite volatility in investing/financing: operating cash flow was $23.9M and free cash flow $19.6M in the quarter. Balance sheet resilience remains mixed but improving—cash is $74.7M and total equity is $359.1M, up from $337.2M QoQ, while long-term debt of $86.2M increased versus Q4’26. Shareholder returns appear pressured: the stock is down 61.6% over 1 year (momentum negative), with no dividend and no buybacks reported in the provided cash flow."

Revenue Growth

Positive

Revenue increased QoQ by 3.1% ($127.1M to $130.9M) and grew YoY by 12.8% ($115.9M to $130.9M), indicating an improving top-line trend.

Profitability

Positive

Net income improved sharply QoQ (+401%) and flipped YoY from -$3.9M to +$6.5M. Net margin expanded to 4.95% from 1.02% QoQ and from -3.38% YoY; operating margin also turned clearly positive.

Cash Flow Quality

Fair

Operating cash flow was $23.9M and free cash flow $19.6M in Q1’27, supporting the earnings rebound. However, financing/investing flows have been volatile across quarters and dividends/buybacks are not evident.

Leverage & Balance Sheet

Caution

Equity increased to $359.1M QoQ, but long-term debt rose to $86.2M. Liquidity is decent with cash of $74.7M, yet net debt remains modestly positive ($11.5M).

Shareholder Returns

Neutral

Total shareholder returns are weak: price is down 61.6% over 1 year. No dividends were paid in the quarter, and no buybacks are shown in the provided cash flow.

Analyst Sentiment & Valuation

Fair

Valuation multiples are elevated (e.g., price-to-sales ~4.29 in the supplied ratios) and the stock trades far below 1-year momentum. The consensus price target (~$21.86) implies upside vs the current price ($9.17), but the 1-year drawdown lowers confidence.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PHR delivered an in-line Q1 FY27 profile with strong Payments momentum and improving profitability. Revenue was $130.9M (+13% YoY) led by 40% Payment Solutions growth, with Network Solutions up 15%. Adjusted EBITDA rose to $30.5M and margins ran at 23%, while net income swung to $3.0M from a net loss in the prior year. The quarter also introduced new payments KPIs (total managed payments $1.786B; Payment Solutions revenue rate 2.3%), clarifying how Access One’s managed portfolio is flowing into monetization. Guidance is unchanged: FY27 revenue $510M-$520M and adjusted EBITDA $125M-$135M, supported by ~$37M Access One contribution and continued mid-/low-single-digit AHSC and revenue-per-AHSC growth. The main macro/forecast risk is Network Solutions variability in 2H driven by client spend pacing and regulatory/brand-specific dynamics. Access One’s PNC securitization expansion (facility cap to $300M; through April 2029) meaningfully increases funding capacity and addressable reach, likely supporting retention and payments-driven economics even as subscription pricing is deliberately moderated.

AI IconGrowth Catalysts

  • Payment Solutions revenue growth +40% YoY driven by Access One (no prior-year contribution because acquisition closed in Q4 FY26)
  • Network Solutions revenue growth +15% YoY supported by momentum from newly launched Provider Connect product
  • Total managed payments platform scaling to $1.786B in Q1 with Payment Solutions revenue rate at 2.3%

Business Development

  • Access One securitization facility expanded with PNC Bank: facility limit increased from $200M to $300M; term extended through April 2029
  • Expanded Access One ability to offer upfront funding to non-investment-grade providers (addressable market expansion referenced alongside PNC amendment)

AI IconFinancial Highlights

  • Revenue $130.9M, +13% YoY; results described as in-line with expectations
  • Adjusted EBITDA $30.5M vs $20.8M prior year; adjusted EBITDA margin 23% (improved from prior-year 20.8M implied margin level but no explicit bps stated)
  • Net income $3.0M vs net loss $(3.9)M prior year; third consecutive quarter of positive net income
  • Average Healthcare Services Clients (AHSC) 4,700: +50 QoQ and +7% YoY (increase from 4,297 to 4,700 implied by 'increase from 297' statement)
  • Total revenue per HIC $27,811, +6% YoY
  • New metrics introduced: total managed payments $1.786B and Payment Solutions revenue rate 2.3%
  • Fiscal 2027 guidance unchanged: revenue $510M-$520M; adjusted EBITDA $125M-$135M

AI IconCapital Funding

  • March 13 refinancing: repaid bridge loan with $92M borrowings from new 5-year $275M senior secured revolving credit facility with Capital One, maturing March 13, 2031
  • New facility usage: $84M borrowings outstanding at April 30, 2026; $8M paydown during the quarter
  • Cash: $76.4M cash/cash equivalents/restricted cash at April 30, 2026 vs $73.8M at Jan 31, 2026; $1.7M restricted cash included with long-term assets
  • Operating cash flow $23.9M; free cash flow $16.4M (both +$9.1M and +$8.9M YoY, respectively)
  • Access One securitization facility with PNC: limit increased to $300M (from $200M) and extended through April 2029

AI IconStrategy & Ops

  • Shift in monetization mix: subscription pricing moderated to support retention while downstream economics improve via Payments and Network Solutions
  • Implementation of restructuring plan in May 2026 (post-quarter): intended to reduce operating expenses and align cost structure; meaningful annualized run-rate savings reflected in FY27 adjusted EBITDA outlook
  • Ongoing automation/efficiency efforts highlighted, including adoption of artificial intelligence to reduce reliance on manual processes

AI IconMarket Outlook

  • FY2027 revenue guidance maintained at $510M-$520M (assumes ~$37M contribution from Access One and no additional revenue from potential future acquisitions completed between now and Jan 31, 2027)
  • FY2027 adjusted EBITDA guidance maintained at $125M-$135M
  • AHSC growth outlook maintained in the mid-single-digit percentage range
  • Total revenue per AHSC outlook maintained to grow in the low single-digit percentage range
  • Management commentary: Network Solutions clients committing lower spend levels in 2H FY27 than anticipated last December; more variability in internal Network Solutions revenue forecasting in 2H each fiscal year

AI IconRisks & Headwinds

  • Network Solutions second-half variability: clients committing lower spend levels due to brand-specific dynamics and regulatory policy impacts (not deemed structural demand shift)
  • Forecasting variability increasing for internal Network Solutions revenue models in 2H of each fiscal year
  • Provider/product success dependent on adoption and engagement; management emphasizes friction reduction via product design rather than creating new problems (implies execution risk)

Q&A: Analyst Interest

  • Access One securitization expansion: analysts asked for quantification of incremental opportunity (cross-selling and economics for non-investment-grade providers). Management emphasized milestone value for expanding addressable market, improving cash flow for providers, and noted economics could differ but was not quantified; more detail pointed to prepared materials and letter.
  • Network Solutions guidance embedded drivers (Provider Connect): analyst sought what is specifically included in FY27 guidance and asked for deeper detail on momentum. Management highlighted two threads: patient intake demand variability and newly launched Provider Connect (started from near zero in FY20), giving a runway for FY28-30 growth beyond Patient Connect.
  • Subscription moderation and sequential decline: analyst questioned why subscription declined 6% sequentially and whether subscription still expects low-single-digit growth later in FY27. Management said revenue-line outlooks are not disclosed; total revenue per AHSC is key and reflects strategy embedded in guidance. They reiterated that the $510M-$520M revenue outlook already captures this trajectory.

Sentiment: MIXED

Note: This summary was synthesized by AI from the PHR Q1 2027 (ended April 30, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PHR.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (PHR)

© 2026 Stock Market Info — Phreesia, Inc. (PHR) Financial Profile